Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTRAVOPROST (travoprost) by Molecular Devices is acid, a prostaglandin analog is a selective fp prostanoid receptor agonist, which is believed to reduce iop by increasing uveoscleral outflow. Approved for prostaglandin analog [epc], elevated intraocular pressure (iop) in patients with open-angle glaucoma, ocular hypertension and 1 more indications. First approved in 2013.
Drug data last refreshed 18h ago
acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Worked on TRAVOPROST at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo